clinical trial · NCT07571161
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
Eli Lilly and Company·phase3·recruiting·n = 140
Alzheimer DiseaseDonanemabPlacebo
brief summary
The main purpose of this study is to evaluate the effects of donanemab (LY3002813) versus placebo in Chinese participants who are at risk for decline of memory, language and physical ability to perform activities of daily living from Alzheimer's disease (AD). The study drug will be administered intravenously (IV) (into a vein in the arm). The study will last up to approximately 156 weeks, excluding screening.
started
Apr 30, 2026
primary completion
Apr 1, 2030
completion
Apr 1, 2030
last updated
Aug 24, 2026
official title
A Study of Donanemab Versus Placebo in Chinese Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol